vaccine
-
Chikungunya vaccine successful in clinical trial
VIENNA, Austria I November 23, 2014 I The Austrian biotech company Themis Bioscience GmbH in collaboration with the Institut Pasteur (Paris, France) have developed a prophylactic vaccine against chikungunya.The vaccine appears to be safe, and produced an immune response that researchers suspect would protect people against infection. The Vienna-based biotech company Themis Bioscience GmbH (‘Themis’) has received final results of…
Read More »